{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:35:32Z","timestamp":1787697332261,"version":"build-2784847793"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ando.2025.101710","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T22:01:10Z","timestamp":1739656870000},"page":"101710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New treatments for acromegaly: Is a revolution underway?"],"prefix":"10.1016","volume":"86","author":[{"given":"Justine","family":"Cristante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-8800","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101710_bib0290","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0295","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ando.2023.08.003","article-title":"Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP)","volume":"84","author":"Brue","year":"2023","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0300","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11102-016-0765-7","article-title":"The surgical treatment of acromegaly","volume":"20","author":"Buchfelder","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2025.101710_bib0305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000201201","article-title":"Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue","volume":"55","author":"Raulf","year":"2009","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.ando.2025.101710_bib0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to somatostatin analogs in acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2025.101710_bib0315","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1093\/ejendo\/lvad097","article-title":"The socioeconomic burden of acromegaly","volume":"189","author":"St\u00f6rmann","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ando.2025.101710_bib0320","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11102-022-01224-0","article-title":"Quality of life after long-term biochemical control of acromegaly","volume":"25","author":"Kimball","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2025.101710_bib0325","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1530\/EJE-14-0844","article-title":"Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey","volume":"172","author":"Sch\u00f6fl","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0330","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s11095-014-1303-9","article-title":"A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms","volume":"31","author":"Tuvia","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.ando.2025.101710_bib0335","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0400","first-page":"dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0405","series-title":"MON-694. Efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled Pathfndr-2 Study","author":"Biller","year":"2024"},{"key":"10.1016\/j.ando.2025.101710_bib0430","unstructured":"Camurus\u2019 octreotide SC depot (CAM2029) achieves superior treatment response compared to placebo in Phase 3 acromegaly trial\u00a0\u2013\u00a0Camurus. June 20, 2023. [Accessed August 13, 2024. https:\/\/www.camurus.com\/media\/press-releases\/2023\/camurus-octreotide-sc-depot-cam2029-achieves-superior-treatment-response-compared-to-placebo-in-phase-3-acromegaly-trial\/]."},{"key":"10.1016\/j.ando.2025.101710_bib0435","first-page":"326","article-title":"A randomised phase 3 trial to assess efficacy and safety of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly","volume":"99","author":"Ferone","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"10.1016\/j.ando.2025.101710_bib0440","article-title":"EP321. An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of the ACROINNOVA 1 roll-over patients subgroup","volume":"Vol 99","author":"Ferone","year":"2024"},{"key":"10.1016\/j.ando.2025.101710_bib0340","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0345","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0355","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0550","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17446651.2016.1222899","article-title":"Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly","volume":"12","author":"Grasso","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0555","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0350","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0360","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1210\/clinem\/dgad365","article-title":"MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly","volume":"108","author":"Fleseriu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2025.101710_bib0370","unstructured":"Mycapssa. European Medicines Agency (EMA). December 22, 2022. [Accessed September 29, 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mycapssa]."},{"key":"10.1016\/j.ando.2025.101710_bib0375","unstructured":"MyCapssa FDA Approval. [Accessed September 29, 2024. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=309310]."},{"key":"10.1016\/j.ando.2025.101710_bib0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ando.2025.101710_bib0385","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2025.101710_bib0390","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0395","unstructured":"ACROBAT Edge Study Of Paltusotine In Acromegaly Met Endpoint. October 26, 2020. [Accessed September 29, 2024. https:\/\/crinetics.com\/acrobat-edge-study-of-paltusotine-in-acromegaly-met-endpoint\/]."},{"key":"10.1016\/j.ando.2025.101710_bib0410","series-title":"MON-695. Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: update from acrobat advance","author":"Gadelha","year":"2024"},{"key":"10.1016\/j.ando.2025.101710_bib0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1773-2247(11)50009-7","article-title":"Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles","volume":"21","author":"Tiberg","year":"2011","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ando.2025.101710_bib0420","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1246\/cl.2012.1090","article-title":"Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions","volume":"41","author":"Tiberg","year":"2012","journal-title":"Chem Lett"},{"key":"10.1016\/j.ando.2025.101710_bib0425","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ando.2025.101710_bib0445","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/endo.142.1.7880","article-title":"Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin","volume":"142","author":"Afargan","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2025.101710_bib0450","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/BF03347512","article-title":"PTR-3173 (Somatoprims\u2122), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion","volume":"27","author":"Shimon","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2025.101710_bib0455","article-title":"GP123. A placebo-controlled study to assess the dose-effect of COR-005, a novel somatostatin analogue on plasma glucose regulation compared to octreotide in healthy male subjects","volume":"Vol 41","author":"Kutz","year":"2016"},{"key":"10.1016\/j.ando.2025.101710_bib0560","doi-asserted-by":"crossref","first-page":"MON-464","DOI":"10.1210\/js.2019-MON-464","article-title":"MON-464 non-clinical profiling of ONO-5788, a novel oral small molecule somatostatin receptor type-2 (SST2) agonist, to support studies in humans","volume":"3","author":"Komagata","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2025.101710_bib0565","unstructured":"Levisetti M. C12. Pharmacokinetics, pharmacodynamics, safety, and tolerability of DP1038, an intranasal formulation of octreotide acetate, in healthy volunteers. [Accessed August 25, 2024. https:\/\/nanets.net\/abstract-posters\/posters-2017\/819-c12-poster-4\/file]."},{"key":"10.1016\/j.ando.2025.101710_bib0570","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1210\/jendso\/bvac150.1095","article-title":"OR27-4 placebo-controlled and open-label extension study of a novel hepatic-targeted antisense cimdelirsen (IONIS-GHR-LRx) under investigation in acromegaly patients","volume":"6","author":"Bhanot","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2025.101710_bib0460","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.jbc.2021.100588","article-title":"A novel peptide antagonist of the human growth hormone receptor","volume":"296","author":"Basu","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ando.2025.101710_bib0465","doi-asserted-by":"crossref","first-page":"A511","DOI":"10.1210\/jendso\/bvac150.1062","article-title":"ODP353 sustained suppression of IGF1 with AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor and a potential new treatment for acromegaly","volume":"6","author":"Culler","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2025.101710_bib0470","article-title":"AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly","volume":"Vol 81","author":"Milano","year":"2022"},{"key":"10.1016\/j.ando.2025.101710_bib0475","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad114.1126","article-title":"THU046 repeated treatment with AZP-3813, a bicyclic, 16-amino acid peptide antagonist of the human growth hormone receptor, induces enhanced suppression of IGF1 in beagle dogs","volume":"7","author":"Ravel","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2025.101710_bib0480","series-title":"ffect of combined treatment with the small peptide GH receptor antagonist, AZP-3813, and the somatostatin analog, octreotide, in decreasing IGF1 levels in the rat","article-title":"Additive e","volume":"Vol 99","author":"Ravel","year":"2024"},{"key":"10.1016\/j.ando.2025.101710_bib0485","article-title":"A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist, in healthy subjects","volume":"Vol 99","author":"Allas","year":"2024"},{"key":"10.1016\/j.ando.2025.101710_bib0490","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1021\/jm050376t","article-title":"Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells","volume":"48","author":"Moore","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.ando.2025.101710_bib0495","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.npep.2018.02.005","article-title":"Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors","volume":"68","author":"Streuli","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ando.2025.101710_bib0500","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12020-017-1386-2","article-title":"Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats","volume":"58","author":"Tarasco","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2025.101710_bib0505","unstructured":"Glyco-Somatostatin. GlyTech, Inc. [Accessed August 25, 2024. https:\/\/www.glytech-inc.com\/pipeline\/gt-02037\/]."},{"key":"10.1016\/j.ando.2025.101710_bib0510","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/17512433.2021.1986004","article-title":"Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly","volume":"14","author":"Neggers","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ando.2025.101710_bib0515","doi-asserted-by":"crossref","first-page":"SAT-432","DOI":"10.1210\/js.2019-SAT-432","article-title":"SAT-432 MTD201 has a favourable 28-day sustained release profile compared to sandostatin LAR in healthy subjects","volume":"3","author":"Seaman","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ando.2025.101710_bib0520","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0525","first-page":"dgae489","article-title":"Paltusotine: a step toward precision medicine in acromegaly","author":"Castinetti","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0530","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101710_bib0535","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/EJE-19-0732","article-title":"The effect of treatment on quality of life in patients with acromegaly: a prospective study","volume":"182","author":"Wolters","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101710_bib0540","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/cen.13331","article-title":"Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study","volume":"86","author":"Kyriakakis","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2025.101710_bib0545","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/03007995.2024.2314244","article-title":"Preferences for different treatment options among people living with acromegaly in the US","volume":"40","author":"Sisco","year":"2024","journal-title":"Curr Med Res Opin"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T08:37:59Z","timestamp":1743928679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0003426625000290"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101710","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments for acromegaly: Is a revolution underway?","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101710"}}